Oaktree Acquisition Corp. III Life Sciences Unit (OACCU) is a dedicated SPAC targeting strategic mergers with pioneering companies within the life sciences sector. Backed by a seasoned management team, OACCU seeks to address pivotal healthcare challenges through investments in pharmaceuticals, biotechnology, and medical technology. With the rapid evolution of the life sciences landscape, OACCU is well-positioned to deliver substantial value for shareholders by enabling innovations that enhance patient outcomes and advance health management solutions.
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | — |
| Operating Margin | 0.00% |
| Return on Equity | 0.00% |
| Return on Assets | -0.38% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $-0.28 |
| Price-to-Book | — |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | 0 |
| Float | $18.37M |
| % Insiders | 3.04% |
| % Institutions | 14.90% |
Volatility is currently contracting